<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01543737</url>
  </required_header>
  <id_info>
    <org_study_id>SNOF EC 01/2010</org_study_id>
    <nct_id>NCT01543737</nct_id>
  </id_info>
  <brief_title>Effectiveness of Two Hyaluronic Acids in Osteoarthritis of the Knee</brief_title>
  <official_title>Single-blind Randomised Pragmatic Trial Comparing the Effectiveness of Two Hyaluronic Acid Viscosupplements, DUROLANE® (Single Injection) Versus HYALGAN® (Three Injections) for Symptomatic Tibiofemoral Osteoarthritis of the Knee.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioventus LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioventus LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether a single injection hyaluronic acid (HA)&#xD;
      product is not inferior to a 3 injection HA product at 24 weeks (6 months), in terms of&#xD;
      effectiveness in reducing pain when walking in patients suffering from symptomatic&#xD;
      tibiofemoral osteoarthritis of the knee.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      non-inferiority study of two HA products commercially availalble&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    post transfer of company ownership from Smith &amp; Nephew to Bioventus LLC&#xD;
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients assessment of WOMAC A1 pain when walking</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients assessment of WOMAC A pain</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients assessment of WOMAC C function</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global assessment</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OMERACT-OARSI responder rate</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Acceptable Symptom State (PASS)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimal Clinically Important Improvement (MCII)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events observed or spontaneously reported by patients for each treatment</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">290</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Single injection hyaluronic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3ml hyaluronic acid (DUROLANE)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Three injection hyaluronic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2ml hyaluronic acid (HYALGAN)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>3ml hyaluronic acid (DUROLANE)</intervention_name>
    <description>DUROLANE Hyaluronic acid 20mg/ml</description>
    <arm_group_label>Single injection hyaluronic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>2ml hyaluronic acid, (HYALGAN)</intervention_name>
    <description>HYALGAN Hyaluronic acid 10mg/ml</description>
    <arm_group_label>Three injection hyaluronic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 40 and &lt; 85&#xD;
&#xD;
          -  Tibiofemoral osteoarthritis of the knee according to the American College of&#xD;
             Rheumatology clinical criteria, in the Kellgren-Lawrence (KL) stages II-III, confirmed&#xD;
             by radiology (&lt; 3 months)&#xD;
&#xD;
          -  Unilateral symptomatic osteoarthritis of the knee causing pain when walking (WOMAC A1&#xD;
             scale), assessed over the previous 24 hours on a scale of 0 to 10: Pain when walking:&#xD;
             ≤ 3 and &lt; 8&#xD;
&#xD;
          -  Bilateral osteoarthritis of the knee, if pain in the other knee is &lt; 3 (10-point&#xD;
             numerical scale)&#xD;
&#xD;
          -  Patient: outpatient, capable of walking 50 metres without a walking stick, crutches or&#xD;
             a walker, capable of reading, understanding, signing and dating the patient&#xD;
             information sheet&#xD;
&#xD;
          -  Patient with social security cover&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Osteoarthritis of the knee in Kellgren-Lawrence (KL) stages I and IV&#xD;
&#xD;
          -  Bilateral symptomatic osteoarthritis of the knee causing pain when walking (WOMAC A1&#xD;
             scale), assessed on a scale of 0 to 10: Pain when walking &gt; 3, in both knees&#xD;
&#xD;
          -  Predominant symptomatic patellofemoral osteoarthritis of the knee&#xD;
&#xD;
          -  Congestive manifestation of osteoarthritis of the knee defined according to the Knee&#xD;
             Osteoarthritis Flare-Ups Score (KOFUS) criteria&#xD;
&#xD;
          -  Last viscosupplementation of the affected knee &lt; 6 months before, last injection of&#xD;
             corticosteroids &lt; 2 months before&#xD;
&#xD;
          -  Known hypersensitivity to avian proteins and hyaluronic acids;&#xD;
&#xD;
          -  History of joint replacement or major surgery in the affected knee in the last six&#xD;
             months&#xD;
&#xD;
          -  History of arthroscopy or surgery in the affected knee in the last three months&#xD;
&#xD;
          -  Symptomatic hip disease on the same side or other side of the body&#xD;
&#xD;
          -  Joint replacement or any other surgery planned in the next six months&#xD;
&#xD;
          -  History of septic arthritis of the affected knee&#xD;
&#xD;
          -  Skin complaint affecting the knee at the injection site&#xD;
&#xD;
          -  Haemorrhagic disease contraindicating, in the doctor's opinion, any intra-articular&#xD;
             injection&#xD;
&#xD;
          -  In order to respect the pragmatic nature of the study:&#xD;
&#xD;
          -  Any medical and / or pathological condition that, in the investigator's opinion, makes&#xD;
             the subject unsuitable for inclusion&#xD;
&#xD;
          -  Any medical and / or pathological condition that, in the investigator's opinion, would&#xD;
             be a contraindication for an intra-articular injection&#xD;
&#xD;
          -  Any other complaint that, in the investigator's opinion, would impede the assessment&#xD;
             of the effectiveness of the affected knee&#xD;
&#xD;
          -  Any treatment administered to the patient that may interfere with the interpretation&#xD;
             of the study results&#xD;
&#xD;
          -  Use of glucocorticosteroids (except inhaled corticosteroids) during the previous month&#xD;
&#xD;
          -  Treatment with diacerein, avocado and soya unsaponifiables, glucosamine sulphate or&#xD;
             chondroitin sulphate, started in the previous 3 months, or irregular doses over the&#xD;
             previous 3 months&#xD;
&#xD;
          -  Hard of hearing (not being able to follow a telephone conversation properly)&#xD;
&#xD;
          -  Patient without a telephone&#xD;
&#xD;
          -  Pregnant women or nursing mothers&#xD;
&#xD;
          -  Participation in other clinical studies, within 30 days before inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Conrozier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lyon University Hospital (HCL)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Argeles-sur-Mer</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Belfort-Montbeliard</name>
      <address>
        <city>Belfort</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Billere</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Cabestany</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical Cabinet Médical</name>
      <address>
        <city>Cornebarrieu</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Metz</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Meulan-les-Mureaux</name>
      <address>
        <city>Meulan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Saint Odilon</name>
      <address>
        <city>Moulins</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Médical Europe</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de l'Appareil Locomoteur - Nollet</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux de Saint Marice</name>
      <address>
        <city>Saint-Maurice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Medical</name>
      <address>
        <city>Valence</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Médical</name>
      <address>
        <city>Villeurbanne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Princesse Grace de Monaco</name>
      <address>
        <city>Monaco</city>
        <country>Monaco</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Monaco</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>February 20, 2012</study_first_submitted>
  <study_first_submitted_qc>March 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2012</study_first_posted>
  <last_update_submitted>February 11, 2016</last_update_submitted>
  <last_update_submitted_qc>February 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

